{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
benzyl benzoate
to a specific field?
Class (Stereo):
CHEMICAL (MIXED)
Amiterol, a phenethylamine derivative, is an oral anti-asthma drug (bronchodilator).
Status:
Investigational
Source:
NCT00000806: Phase 1 Interventional Completed HIV Infections
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Telinavir (previously known as SC-52151) was developed as an anti-HIV aspartyl protease inhibitor for the treatment of HIV Infections. Telinavir participated in Phase I/II clinical study. In spite of the drug was well tolerated no antiviral activity was produced and further development of the drug was discontinued.
Class (Stereo):
CHEMICAL (ACHIRAL)
Milfasartan is an inhibitor of angiotensin II receptor type 1 was used in phase II clinical trial for the treatment of hypertension. However, these studies were discontinued.
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Myrophine is an opiate analog and long-acting prodrug for morphine with a slow onset of effects. It is weaker than morphine as an analgesic but longer-lasting in effects and was thought to have a more local anesthetic effect than morphine, though with a somewhat greater tendency to cause histamine reactions like itching and rash. In addiction studies conducted in human subjects in the 1950s, myrophine did not substitute for morphine in withdrawal, did not produce notable morphine-like effects, and did not produce addiction or dependence regardless of dose or how it was administered.
Class (Stereo):
CHEMICAL (MIXED)
Englitazone is a thiazolidinedione antidiabetic agent. It has insulinomimetic and insulin-enhancing actions in vitro and glucose-, insulin-, triglyceride-, and cholesterol-lowering properties in an animal model of non-insulin-dependent diabetes mellitus. It acts as a peroxisome-proliferator-activated receptor-gamma ligand. Englitazone inhibits ATP-sensitive potassium and calcium-activated non-selective cation channels in a voltage-independent manner.
Status:
Investigational
Source:
INN:pyrrolifene [INN]
Source URL:
Class (Stereo):
CHEMICAL (UNKNOWN)
Pyrroliphene is a dialkylaminodiphenylbutanol ester with antitussive and analgesic activities. In clinical trials the major side effect of Pyrroliphene was sedation, and the other side effect liabilities were similar to those of morphine.
Status:
Investigational
Source:
NCT00143520: Phase 2/Phase 3 Interventional Completed Type 2 Diabetes
(2004)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Rivoglitazone hydrochloride (CS-011) is a thiazolidinedione-derivative peroxisome proliferator–activated receptor (PPAR)-γ agonist. It has been developed as potential treatment in type 2 diabetes mellitus and was shown to decrease plasma glucose and triglyceride levels in a dose-dependent manner in animals. Phase II and III clinical studies have assessed the efficacy and safety of rivoglitazone hydrochloride in patients with type 2 diabetes mellitus.
Class (Stereo):
CHEMICAL (ACHIRAL)
Benhepazone (also known as RCH-314) possessed potent analgesic and anti-inflammatory activities. Information about the nowadays use of this compound is not available.
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
FEPRADINOL is an analgesic, antipyretic and anti-inflammatory agent. Its anti-inflammatory activity does not seem to be related to an inhibitory effect on prostaglandin biosynthesis.
Status:
Investigational
Source:
NCT00257621: Phase 2 Interventional Completed Infection, Human Immunodeficiency Virus I
(2004)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Brecanavir (previously known as VX-385), a HIV aspartyl protease inhibitor was developed for the treatment of HIV. The inhibition of HIV viral proteinase enzyme prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. Brecanavir reached Phase II development. However, GlaxoSmithKline announced to discontinue development brecanavir. Because of the inability to develop a viable oral dosage formulation capable of delivering the desired brecanavir levels in patients with multi-drug resistant HIV.
